Atai Life Sciences NV 10-Q quarterly reports

Atai Beckley N.V. reported increased net losses for Q3 2025, driven by higher operating expenses, but secured significant capital and advanced its psychedelic-based neuroplastogen pipeline, including a Breakthrough Therapy designation for BPL-003.

ATAI Life Sciences N.V. reported a significantly reduced net loss for the first half of 2025, bolstered by successful capital raises and positive clinical data for BPL-003, despite a delay in its VLS-01 program.

ATAI Life Sciences reports its financial results for the first quarter of 2025, providing updates on its clinical-stage pipeline and strategic initiatives.

ATAI Life Sciences N.V. has filed an amendment to its quarterly report to correct signature omissions in certifications, with no changes to the financial data.

ATAI Life Sciences reported a net loss of $110.3 million for the first nine months of 2024, alongside updates on its clinical pipeline and strategic initiatives.

ATAI Life Sciences reported its Q2 2024 financial results, highlighting a net loss but also progress in its clinical programs and strategic capital allocation.

ATAI Life Sciences reports a net loss of $26.7 million for Q1 2024, while advancing clinical programs and making strategic investments.